Ipsen acquires Simcere Zaiming’s innovative ADC SIM0613
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
Subscribe To Our Newsletter & Stay Updated